Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13)

Magnitude and risk factors

From:
Department for International Development
Published
8 April 2019
Country:
China
Document Type:
Journal Article
Theme:
Health
Authors:
Xu, C, Li, R, Shewade, H.D., Jeyashree K

Abstract

China’s national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. Under the Global Fund programmatic management of drug-resistant TB (2006–13), the authors assessed the attrition and delay in the pathway and the factors associated.

This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)

Citation

Xu C, Li R, Shewade HD, Jeyashree K, Ruan Y, Zhang C, Wang L, Zhang H. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors. PLOS ONE. 2019;14(4):e0214943.

Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors

Updates to this page

Published 8 April 2019
Contents